Acute Myeloid Leukemia Clinical Trials

There are 24 registered clinical trials for Acute Myeloid Leukemia in the TrialLens index.

Trials (24)

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Multiple CAR-T Cell Therapy Targeting AML Phase 1/2 · Shenzhen Geno-Immune Medical Institute
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML Phase 1/2 · The Korean Society of Pediatric Hematology Oncology
MG4101 for Refractory or Relapsed AML Phase 2 · Seoul National University Hospital
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 1/2 · Vanderbilt-Ingram Cancer Center
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML Phase 1 · Masonic Cancer Center, University of Minnesota
Long-term Outcomes for Acute Myeloid Leukemia Patients N/A · Gruppo Italiano Malattie EMatologiche dell'Adulto
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 2 · Bio-Cancer Treatment International Limited
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias Phase 1 · UNC Lineberger Comprehensive Cancer Center
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Phase 2 · Rutgers, The State University of New Jersey
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase 1/2 · Fred Hutchinson Cancer Center
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia N/A · Hospices Civils de Lyon
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection N/A · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia N/A · University of Chicago
Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia N/A · Université Catholique de Louvain
Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide Phase 3 · University Hospital Muenster
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2 · Fred Hutchinson Cancer Center
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients Phase 2 · Chinese PLA General Hospital
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation Phase 2 · Massachusetts General Hospital
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia Phase 1 · M.D. Anderson Cancer Center
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Phase 1 · AbbVie
Menin-Inhibitor Targeted Maintenance in AML Phase 2 · Center for International Blood and Marrow Transplant Research
Mismatched Donor Cells to Treat Acute Myeloid Leukemia Phase 1 · Maisonneuve-Rosemont Hospital

Related landscapes

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.